

The value of HPV-HR DNA testing during the follow-up after treatment of CIN3/AIS

Banović, Maja; Mahovlić, Vesna; Meljanac Salopek, Kristina; Banović, Vladimir; Babić, Ivan; Orešković, Slavko; Babić, Damir

Source / Izvornik: **Pathology Oncology Research, 2015, 21, 613 - 617**

Journal article, Accepted version

Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

<https://doi.org/10.1007/s12253-014-9865-8>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:105:962244>

Rights / Prava: [In copyright](#)/[Zaštićeno autorskim pravom.](#)

Download date / Datum preuzimanja: **2025-04-02**



Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine
Digital Repository](#)





Središnja medicinska knjižnica

Banović M., Mahovlić V., Meljanac Salopek K., Banović V., Babić I., Orešković S., Babić D. (2015) *The value of HPV-HR DNA testing during the follow-up after treatment of CIN3/AIS. Pathology Oncology Research, 21 (3). pp. 613-7. ISSN 1219-4956*

<http://www.springer.com/journal/12253>

<http://link.springer.com/journal/12253>

The final publication is available at Springer via
<http://dx.doi.org/10.1007/s12253-014-9865-8>

<http://medlib.mef.hr/2519>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

TITLE PAGE

Article title: The value of HPV-HR DNA testing during the follow-up after treatment of CIN3/AIS

Authors and affiliations:

Maja Banović, MD; University of Zagreb, School of Medicine, Clinical Hospital Center Zagreb, Dept. of Obstetrics and Gynecology, Croatia.

Vesna Mahovlić, MD, PhD; University of Zagreb, School of Medicine, Clinical Hospital Center Zagreb, Dept. of Pathology and Cytology, Croatia.

Kristina Meljanac Salopek, PhD; University of Zagreb, School of Medicine, Dept. of Pathology, Croatia.

Vladimir Banović, MD, PhD; University of Zagreb, School of Medicine, Clinical Hospital Center Zagreb, Dept. of Obstetrics and Gynecology, Croatia.

Ivan Babić, MD, University of Zagreb, School of Medicine, Clinical Hospital Center Zagreb, Dept. of Obstetrics and Gynecology, Croatia.

Slavko Orešković, MD, PhD; University of Zagreb, School of Medicine, Clinical Hospital Center Zagreb, Dept. of Obstetrics and Gynecology, Croatia.

Damir Babić, MD, PhD; University of Zagreb, School of Medicine, Clinical Hospital Center Zagreb, Dept. of Pathology and Cytology, Croatia.

Corresponding author:

Maja Banović, MD; University of Zagreb, School of Medicine, Clinical Hospital Center Zagreb, Dept. of Obstetrics and Gynecology, Croatia.

Petrova 13

10000 Zagreb, Croatia

Fax 0038514633512

Phone: 0038514604616

e-mail: mzanko03@gmail.com

Abstract

There is still debate on what is the optimal follow-up protocol after a treatment for preinvasive cervical disease. We performed this study in order to improve diagnostic accuracy of the follow-up protocol and at the same time reducing the number of overtreated patients. One hundred and fourteen patients were followed up after conization for CIN3 and/or AIS at 3-6 month, 9-12 month and 18-24 month intervals, then yearly. The follow-up consisted of cytology, colposcopy with biopsy if needed and HPV testing. The end-point of the study was a secondary treatment due to a high suspicion of residual/recurrent disease or disease free period of at least 24 months. The median follow-up time was 41 months (5-72 months). In predicting residual/recurrent disease cytology had a specificity of 88.9%, sensitivity of 100%, PPV of 33.3% and a NPV of 100% whereas HPV had a specificity of 76.9%, sensitivity of 100%, PPV of 21.4% and a NPV of 100%. According to our results both tests can be used as a primary follow-up tool after conization. The choice should depend on a socio-economic aspect. In our setting the HPV test should be done only in those patients with a positive smear any time during follow-up as the point of decision for a second treatment. With this approach we could considerably decrease the number of reoperated patients and co-morbidities.

Key words: human papillomavirus, preinvasive cervical disease, postconisation, HPV DNA test, follow-up

Introduction

The fact that up to 30% of women treated for a preinvasive cervical disease are diagnosed with a residual/recurrent disease including an invasive carcinoma during follow-up, requires close surveillance of these patients [1]. The majority of cases (80-90%) are detected during the first two years after conization [2]. This in part justifies the anxiety of patients and gynecologists in fearing insufficient treatment or recurrence of the disease and that can lead to over-surveillance and overtreatment. We must keep in mind that these patients are mostly of childbearing age and desire preservation of fertility. Repeated treatments on the cervix can cause negative sequelae in their reproductive health [3].

Cytology, colposcopy and HPV testing during the follow-up have some downfalls compared to primary screening. Removal of the transformation zone at conization and scarring after surgery often makes colposcopy unsatisfactory and unreliable, especially when the cold-knife method is used [4]. Cytology is burdened with reparative and proliferative healing process of the epithelium. Conization removes the dysplastic lesion but not necessarily all the normal epithelium infected by HPV. Being aware of this we must use these tools in the best cost-effective protocol, which will be most accurate in diagnosis and sparing in treatment. Studies have shown a higher sensitivity in detection of residual/recurrent disease with the use of combined testing (cytology and HPV) [5,6]. Combined testing raises the cost of follow-up and in some countries like Croatia, with a tradition of high quality cytology this is unacceptable. Therefore we performed this study with intention to improve diagnostic accuracy of the follow-up protocol after conization keeping it safe and cost-effective and at the same time reducing the number of overtreated patients.

Materials and methods

The study was conducted at the Department of Obstetrics and Gynecology, University Hospital in Zagreb from 1st January 2008 until 1st January 2014. One hundred and thirty five patients treated with cold-knife conization (CKC) or large loop excision of the transformation zone (LLETZ) for a preinvasive cervical disease, were enrolled in the study. The study inclusion criteria were: cervical intraepithelial neoplasia grade 3 (CIN3) and/or adenocarcinoma in situ (AIS) confirmed at conization; no previous history of cervical pathology; not pregnant; no concomitant cancer or immunosuppressive disease. All of the participants signed an informed consent before entering the study. Control visits were scheduled at 3-6 month, 9-12 month and 18-24 month intervals. If testing results were negative during the first two years, follow up visits were re-scheduled yearly. The follow-up consisted of cytology, colposcopy with biopsy if needed and HPV testing. Only patients with at least two cytology smears and one HPV test during the first two post-treatment years remained in the study. The end-point of the study was a secondary treatment (reconization or hysterectomy) or disease free period of at least 24 months. Indication for a second treatment was based on a positive cytology smear (HSIL/AGC/AIS) and unsatisfactory or positive colposcopy finding. The cytology smear was taken using liquid based cytology (LBC) ThinPrep© (Hologic, Inc Corp. Mariborough, MA) or the conventional Papanicolaou. Cervical smears were classified according to the Bethesda System 2006 - Zagreb modification and dichotomized into positive (\geq H-SIL/AGC/AIS) or negative [7]. Since HPV testing was used for the evaluation of the current follow-up policy, test results were blinded until the analysis. The HPV test was performed by EIA PCR using a HPV-general-primer-mediated PCR. A β -globin PCR was performed to ascertain the quality of the target DNA. All 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) were tested for in one assay. Where possible, genotyping was performed before conization by Line immuno Probe Assay (Inno-LiPA) genotyping v2 system (Innogenetics, Gent, Belgium).

The statistic analysis was performed using the χ^2 test in analysis of frequency tables for independent categorical variables. Additionally, McNemar's test for trends was used to assess follow-up differences. Kappa coefficients (k=coefficient of agreement) were calculated to analyze consistencies and agreement between test results during the follow-up period. Performance indicators and diagnostic accuracy were calculated using the contingency tables for sensitivity, specificity, positive (PPV) and negative predictive value (NPV), with corresponding 95% confidence intervals

(CI). In all tests P values below 0.05 were regarded as statistically significant. Calculations were performed using the StatsDirect Statistical Software version 2.7.8 (www.statsdirect.com).

Results

Data was analyzed for 114 patients, since 21 were lost to follow-up. The median follow-up time was 41 months (5-72 months). Cone histology showed CIN3 in 101 (88.6%) and AIS in 13 (11.45%) patients. In six patients with AIS there were also CIN3 changes (46.2%). Most of the patients were younger than 40 (64.9%; median 35.0, interquartile range 30.0-43.3; range 18–66 years) and 31 (27.2%) patients were nulliparous prior to conization. Histology diagnosis (CIN3/AIS) didn't differ significantly between age groups ($P=0.402$) however, the number of women younger than 30 was more frequent in the AIS group (38.5% vs 21.8%). All of the women that had HPV testing before conization ($N=39$) were HPV positive. Thirty-one (79.5%) patients had a mono-infection, but a multiple infection was more common in patients younger than 40 ($P=0.045$). The most common genotype isolated was HPV16 in both types of infection, being present in 25 (64.2%) patients. Genotype distribution was related to histology since HPV18 had only been isolated in AIS specimens ($P=0.036$).

The primary treatment was by cold-knife conization in 98 (86%) and LLETZ in 16 (14%) patients. Positive margins were found in 20 (17.5%) cone specimens and were more common in the LLETZ group ($P=0.024$). During the follow-up 11 (9.6%) patients had a second surgery due to a suspicion of residual/recurrent disease. In four patients reoperation was done (36.4%) during the first six months after conization and in seven (63.6%) during the following 18 months. Four (36.4%) patients had hysterectomy and seven (63.6%) had reconization done. Histology revealed no evidence of preinvasive or invasive diseases in five (45.5%) of these patients. Four patients were confirmed with CIN 2,3 and two had an invasive carcinoma.

Margin involvement was not related to a decision to perform a second treatment ($P=0.084$). Still, in patients with positive cytology those with involved margins were more likely to have a residual/recurrent disease ($P=0.022$). There was no correlation between the type of HPV infection before conisation and the residual/recurrent disease ($P=0.581$).

Figure 1 shows distribution of positive cytology and HPV during the follow-up. The highest frequency of positive cytology smears was in the 3-6 month interval ($P<0.001$). There was no difference in HPV test results distribution between follow-up intervals. In all three intervals HPV test was more frequently positive than cytology smears and the biggest difference was in the 18-24 month interval ($P=0.010$). There was a high concordance of cytology and HPV test results during the whole follow-up period (Fig. 2). Cytology smears were most consistent between 3-6 month and 9-12 month

intervals ($k=0.458$, $P<0.001$). HPV test results between follow-up intervals were inconsistent and had a low coefficient of agreement. Best agreement was found between HPV at 3-6 month interval and cytology at 9-12 month interval follow-up ($k=0.559$, $P<0.001$).

Both cytology ($P<0.001$) and HPV test ($P=0.015$) results correlated with a decision to perform a second treatment. Cytology had a PPV of 61.1% (CI 35.8-82.7), a NPV of 100% (CI 96.3-100), whereas HPV test had a PPV of 21.4% (CI 8.3-41), a NPV of 94.2% (CI 87-98.1). The performance of cytology and HPV test in detecting a residual/recurrent disease is shown in Table 2. There was no residual/recurrent disease when posttreatment cytology or HPV test was negative. In the group of patients with positive cytology 33.3% had a residual/recurrent disease, whereas among those HPV positive 21.4% had a residual/recurrent disease. All of the patients who had a residual/recurrent disease were HPV positive, and 75% of disease-free patients were HPV negative.

Discussion and conclusion

Women treated for a preinvasive cervical disease are mostly of reproductive age and still desire pregnancy, as were the majority of women in our study, therefore the approach in treatment and follow-up has to be safe and sparing. Negative follow-up test results whether it'd be only cytology, only HPV or a combined test, give a reassuring low risk of 5-year recurrence of CIN2+ lesion [8]. In our study both cytology and HPV showed a good performance in detecting a residual/recurrent disease (Table 2) with sensitivity of 100% and NPV of 100% for both tests. Women not reoperated remained disease free up to 72 months (4-7 years) after conization. However, in the reoperated group 45.5% had no residual/recurrent disease in the histology report. We can argue that these patients were unnecessarily exposed to peri- and postoperative morbidity. Some other studies also found a relatively high number of reoperated patients who had no residual/recurrent disease confirmed [4,9]. The decision for a second treatment in our study relied upon cytology and colposcopy protocol, mainly (81.2%) during the first year of follow-up. Histology reports were mostly negative in those reoperated 6 months after conization, which confirms findings of some other authors that this protocol is more often false-positive in the early follow-up period [10].

During the whole follow-up period the concordance of cytology and HPV test results was high (Fig. 2) and almost 70% of patients had both tests negative, which corresponds to results of other studies (14). Given the high sensitivity and concordance in our results we conclude that in our setting (with poorer resources and high quality cytology) it is not cost-effective to perform both tests to all women after conization. Gok et al suggested that patients at the highest risk for residual/recurrent disease are those with HPV16 infection prior to conization and that they should have a combined test done 6 months after conization [11]. Considering that HPV infection is alluded in biopsy proven CIN/AIS lesions and the fact that most women in our study tested before conization had HPV16 and/or 18 positive (74.5%), we don't think genotyping improves the quality of follow-up but only raises the cost. Given that HPV test results between follow-up intervals in our study had a low coefficient of agreement and that natural history of viral infection depends on individual's characteristics [12] it is questionable if we can rely on one-fold testing without the reassurance of cytology. The highest incidence of a positive HPV test was during the second year of follow-up ($P=0.010$), which can be explained by individual's sexual behavior. Protocols including the HPV test have shown that the optimal HPV clearance after conization is 6 months posttreatment [13].

Many studies have shown that combined testing has the highest sensitivity in detecting a residual/recurrent disease [14]. According to our results both tests show a very good performance in detecting a residual/recurrent disease so depending on the socio-economic aspect both can be used as a primary follow-up tool after conization. In our study specificity of cytology (88.9%) was higher than of HPV (79.6%) in detecting a residual/recurrent disease thus the choice of cytology as the first follow-up test after conization in our setting is obvious, whereas others can choose the HPV test instead. In each case if the chosen test is positive the other one has to be performed as well before deciding on a further procedure. In our study HPV test would have improved the specificity of cytology/colposcopy-based protocol in the group of reoperated patients since all of the patients with proven residual/recurrent disease were HPV positive whilst those with negative histology were HPV negative. Time interval from conization didn't influence test performance in this group ($P < 0.001$). In all follow-up intervals in case of positive cytology and/or inconclusive colposcopy a negative HPV test can give reassurance and reduce anxiety without hurrying with a second treatment but repeating the cytology smear in another 3-4 months, considering that there is no suspicion of invasive disease. In these cases LBC has advantage compared to conventional PAP smear since there is no need to invite the patients for another visit.

The follow-up after conization must ensure safety and reassurance of both patients and gynecologists, but at the same time it must be cost-effective. Mentioned downfalls of surveillance tools can lead to overtreatment therefore, if cytology or HPV is positive we strongly recommend that the other test be performed as well before any other procedure. Results of our study suggest that in our setting the best approach is to have a first control cytology smear six months after conization. HPV test should be done in patients with a positive smear any time during follow-up as the point of decision for a second treatment. With this approach we could considerably decrease the number of reoperated patients and co-morbidities without decreasing the quality of follow-up.

Fig. 1. The percentage of positive cytology smears and HPV tests during the follow-up




Fig. 2. Distribution of concordant and non-concordant test results during the follow-up




Table 1. Distribution of reoperated patients during the follow-up

Case no.	Age at conization	PHD 1	Cytology prior to 2nd treatment	HPV infection prior to 2nd treatment	Interval between treatments (months)	PHD 2
1	38	CIN 3	HSIL	Positive	11	Positive
2	31	CIN3	HSIL	Positive	10	Positive
3	44	CIN3	HSIL	Negative	11	Negative
4	43	CIN3	HSIL	Positive	7	Positive
5	46	CIN3	HSIL	Negative	5	Negative
6	54	CIN3	HSIL	Positive	24	Positive
7	37	AIS	AGC	Negative	5	Negative
8	31	AIS	HSIL, AGC	Positive	19	Positive
9	43	AIS	HSIL, AIS	Negative	5	Negative
10	31	AIS	AGC	Negative	5	Negative
11	38	CIN3	HSIL	Positive	8	Positive

Table 2. Performance of cytology and HPV test in detection of residual/recurrent disease

	Cytology % (CI)	HPV % (CI)
Sensitivity	100 (54.1-100)	100 (54.1-100)
Specificity	88.9 (81-94.1)	79.6 (70.8-86.8)
PPV	33.3 (13.3-59)	21.4 (8.3-41)
NPV	100 (96.2-100)	100 (95.8-100)

References

1. Nuovo J, Melnikow J, Willan AR, Chan BK (2000) Treatment outcomes for squamous intraepithelial lesions. *Int J Gynaecol Obstet* Jan;68(1):25-33.
2. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G et al (2012) Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. *Vaccine* Nov 20;30 Suppl 5:F88-99.
3. MartinHirsch PL, Paraskevaidis E, Kitchener H (2000) Surgery for cervical intraepithelial neoplasia. *Cochrane Database Syst Rev* 2000;(2):CD001318.
4. Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS (2007) Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. *Int J Gynecol Cancer* Nov-Dec;17(6):1271-7.
5. Prato B, Ghelardi A, Gadducci A, Marchetti I, Di Cristofano C, Di Coscio G et al (2008) Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. *Int J Gynecol Cancer* Jan-Feb;18(1):90-4.
6. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M et al (2003) Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. *Gynecol Oncol* Aug;90(2):358-65.
7. Ovanin-Rakić A, Pajtler M, Stanković T et al (2003) [Classification of cytologic cervical smears ‘‘Zagreb 2002’’. Modification of classifications ‘‘Zagreb 1991 and NCI Bethesda system 2001’’]. *Gynaecol Perinatol* 12:148-53.
8. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK (2013) Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. *J Low Genit Tract Dis.* 2013 Apr;17(5 Suppl 1):S78-84. doi: 10.1097/LGT.0b013e31828543c5.
9. Almog B, Gamzu R, Bornstein J, Levin I, Fainaru O, Niv J, Lessing JB, Bar-Am A (2003) Clinical and economic benefit of HPV-load testing in follow-up and management of women postcone biopsy for CIN2-3. *Br J Cancer* Jul 7;89(1):109-12.

10. Coupe VM, Berkhof J, Verheijen RH, Meijer CJ (2007) Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. *BJOG* Apr;114(4):416-24.
11. Gök M, Coupé VM, Berkhof J, Verheijen RH, Helmerhorst TJ, Hogewoning CJ et al (2007) HPV16 and increased risk of recurrence after treatment for CIN. *Gynecol Oncol* Feb;104(2):273-5.
12. Stanley M (2010) Pathology and epidemiology of HPV infection in females. *Gynecol Oncol* May;117(2 Suppl):S5-10. doi: 10.1016/j.ygyno.2010.01.024
13. Du R, Meng W, Chen ZF, Zhang Y, Chen SY, Ding Y (2013) Post-treatment human papillomavirus status and recurrence rates in patients treated with loop electrosurgical excision procedure conization for cervical intraepithelial neoplasia. *Eur J Gynaecol Oncol* 34(6):548-51.
14. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ (2004) HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. *Obstet Gynecol Surv* Jul;59(7):543-53.
15. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH (2009) Human papillomavirus test after conization in predicting residual disease in subsequent hysterectomy specimens. *Obstet Gynecol* Jul;114(1):87-92. doi: 10.1097/AOG.0b013e3181ab6dca.